Summary of Significant Accounting Policies - Schedule of Concentration (Details)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Janssen | Accounts Receivable | Credit Concentration Risk
Revenue Initial Application Period Cumulative Effect Transition [Line Items]
Concentration risk percentage	30.00%	29.00%	27.00%
Janssen | Revenues Net | Customer Concentration Risk
Revenue Initial Application Period Cumulative Effect Transition [Line Items]
Concentration risk percentage	33.00%	28.00%	29.00%
Biogen | Revenues Net | Customer Concentration Risk
Revenue Initial Application Period Cumulative Effect Transition [Line Items]
Concentration risk percentage		17.00%	10.00%
Cardinal Health | Accounts Receivable | Credit Concentration Risk
Revenue Initial Application Period Cumulative Effect Transition [Line Items]
Concentration risk percentage	16.00%	12.00%
Cardinal Health | Revenues Net | Customer Concentration Risk
Revenue Initial Application Period Cumulative Effect Transition [Line Items]
Concentration risk percentage	21.00%		13.00%
AmerisourceBergen | Accounts Receivable | Credit Concentration Risk
Revenue Initial Application Period Cumulative Effect Transition [Line Items]
Concentration risk percentage	11.00%	10.00%
AmerisourceBergen | Revenues Net | Customer Concentration Risk
Revenue Initial Application Period Cumulative Effect Transition [Line Items]
Concentration risk percentage	10.00%
McKesson | Revenues Net | Customer Concentration Risk
Revenue Initial Application Period Cumulative Effect Transition [Line Items]
Concentration risk percentage	14.00%
Acorda | Accounts Receivable | Credit Concentration Risk
Revenue Initial Application Period Cumulative Effect Transition [Line Items]
Concentration risk percentage			15.00%
Acorda | Revenues Net | Customer Concentration Risk
Revenue Initial Application Period Cumulative Effect Transition [Line Items]
Concentration risk percentage			10.00%